InspireMD reports 100% device success in CGuard Prime TCAR trial
InspireMD announced positive 30-day results from CGUARDIANS II trial showing 100% acute device success with zero major adverse events for its CGuard Prime 80cm stent in TCAR procedures. The company expects FDA approval in H2 2026, potentially expanding its addressable market to include transcarotid artery revascularization procedures alongside carotid artery stenting.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day